Although research is being conducted on new anthelmintics and ectoparasiticides, we simply cannot afford a cavalier attitude with regard to our current compounds since new antiparasitics tend to appear on the market relatively infrequently (Geary et al., 1999). The pivotal role that MLs now play in the control of many of our most important parasitic diseases suggests that the conservation of efficacy of these compounds should be given some priority in the allocation of research and advisory funding by both the industry and academia.

0 0

Post a comment